Clear cell renal cell carcinoma (ccRCC) is the most common histologic subtype of renal cell carcinoma, arising from kidney tubular epithelium and characterized by clear cytoplasm on pathology. It is the predominant malignant kidney cancer subtype in adults.
Bristol Myers Squibb started a Phase 1 trial of BMS-986506 in clear cell renal cell carcinoma, triggering a $10 million milestone payment to Evotec SE. The candidate is the first molecular glue from the companies’ protein-degradation partnership to enter human testing.
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
Phase III trial demonstrates belzutifan plus lenvatinib significantly improved progression-free survival versus cabozantinib in previously treated renal cell carcinoma patients, while neoadjuvant studies show promise for locally advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602101 |
Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07564232 |
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07516366 |
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07469683 |
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma |
RECRUITING | PHASE2 |
| NCT07389629 |
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC |
RECRUITING | PHASE2 |
| NCT07300241 |
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma |
RECRUITING | PHASE1 |
| NCT07227415 |
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07223541 |
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma |
RECRUITING | PHASE2 |
| NCT07187869 |
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study |
NOT_YET_RECRUITING | PHASE1 |
| NCT07187778 |
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) |
RECRUITING | PHASE2 |
